ангиотензин II 和动脉样硬化:超越高血压的新型心血管风险因素
Nicola Morat1, Giovanni Civieri1, Matteo Spezia2
1Cardiology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
International journal of molecular sciences
|August 14, 2025
概括
ангиотензин II (AngII) 在高血压之外的心血管疾病中起着显著的作用. 本综述探讨了它在动脉样硬化发展和进展中的作用,重点介绍了renin-angiotensin-aldosterone系统.
科学领域:
- 心血管科学 心血管科学
- 内分泌学 在内分泌学.
- 病理生理学 病理生理学
背景情况:
- ангиотензин II (AngII) 是心血管疾病的一个关键因素,已建立的疗法针对其抑制.
- AngII型1受体调解AngII的影响,导致高血压,心脏和血管重塑以及器官损伤.
研究的目的:
- 审查AngII和renin-angiotensin-aldosterone系统在心血管风险中的作用.
- 探索AngII与动脉样硬化发展和进展之间的联系,超越高血压.
主要方法:
- 文献综述综合了AngII,氨酸-血管酶-氨系统和心血管疾病的现有研究.
- 专注于研究AngII对动脉样硬化的影响.
主要成果:
- 它的1型受体的AngII激活会触发细胞反应,导致心血管病理.
- 氨酸- ангиотензин- алдостерон系统对心血管风险的影响延伸到动脉样硬化.
结论:
- AngII在心血管疾病的发病过程中发挥着关键作用,包括动脉样硬化.
- 了解AngII的多方面的作用对于管理心血管风险至关重要.
相关概念视频
Hypertension II: Pathophysiology
78
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
78
Antihypertensive Drugs: Angiotensin II Receptor Blockers
920
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
920
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
881
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
881
Coronary Artery Disease I: Introduction
55
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
55
Antihypertensive Drugs: Direct Renin Inhibitors
823
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
823
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508


